Literature DB >> 23052222

Dose-dependent short-term effects of single high doses of oral vitamin D(3) on bone turnover markers.

Maurizio Rossini1, Silvano Adami, Ombretta Viapiana, Elena Fracassi, Luca Idolazzi, Maria Rosaria Povino, Davide Gatti.   

Abstract

We investigated the short-term effects on bone turnover markers of high doses of vitamin D(3) in order to identify what initial therapeutic dose can be safely administered in vitamin D-deficient subjects. Thirty-seven elderly subjects [mean age 75 ± 3 (SD) years] were consecutively randomized to the administration of a single oral bolus of 600000, 300000, or 100000 IU vitamin D(3). Blood samples were taken at baseline and 1, 3, 7, 14, 30, 60, and 90 days after vitamin D(3) administration. Twenty-four subjects served as controls. No relevant changes in bone turnover markers [C-terminal telopeptides of type I collagen (sCTX) and bone-specific alkaline phosphatase (BAP)] were observed in the controls. In treated patients a dose-dependent effect on sCTX was observed. With the administration of 600,000 IU vitamin D(3) a significant increase of sCTX was observed already at day 1, and it was sustained for 2 months. The changes in sCTX with smaller doses were considerably lower and reached statistical significance only within the first 3 days with the 300,000 IU dose. BAP remained unchanged in patients given 300,000 and 600,000 IU vitamin D(3), while it significantly rose by 15-23 % throughout the observation period in patients given 100,000 IU. Our results indicate that the use of a vitamin D bolus exceeding 100,000 IU may be associated with acute increases of sCTX.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23052222     DOI: 10.1007/s00223-012-9637-y

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  19 in total

1.  Bone turnover markers, BMD and TBS after short-term, high-dose glucocorticoid therapy in patients with Graves' orbitopathy: a small prospective pilot study.

Authors:  S Censi; J Manso; G Pandolfo; G Franceschet; E Cavedon; Y H Zhu; S Carducci; W Gomiero; M Plebani; M Zaninotto; S Watutantrige-Fernando; C Mian; V Camozzi
Journal:  J Endocrinol Invest       Date:  2018-12-05       Impact factor: 4.256

Review 2.  The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).

Authors:  Luisella Cianferotti; Claudio Cricelli; John A Kanis; Ranuccio Nuti; Jean-Y Reginster; Johann D Ringe; Rene Rizzoli; Maria Luisa Brandi
Journal:  Endocrine       Date:  2015-05-01       Impact factor: 3.633

Review 3.  Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues?

Authors:  I R Reid; M J Bolland
Journal:  Osteoporos Int       Date:  2014-05-21       Impact factor: 4.507

4.  Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens.

Authors:  S Minisola; L Cianferotti; P Biondi; C Cipriani; C Fossi; F Franceschelli; F Giusti; G Leoncini; J Pepe; H A Bischoff-Ferrari; M L Brandi
Journal:  Osteoporos Int       Date:  2017-08-16       Impact factor: 4.507

Review 5.  Vitamin D supplementation, body weight and human serum 25-hydroxyvitamin D response: a systematic review.

Authors:  Armin Zittermann; Jana B Ernst; Jan F Gummert; Jochen Börgermann
Journal:  Eur J Nutr       Date:  2013-12-01       Impact factor: 5.614

6.  Effect of isolated vitamin D supplementation on bone turnover markers in younger postmenopausal women: a randomized, double-blind, placebo-controlled trial.

Authors:  J Nahas-Neto; L M Cangussu; C L Orsatti; F N Bueloni-Dias; P F Poloni; E B Schmitt; E A P Nahas
Journal:  Osteoporos Int       Date:  2018-02-15       Impact factor: 4.507

7.  Randomized clinical trial to comparing efficacy of daily, weekly and monthly administration of vitamin D3.

Authors:  István Takács; Béla E Tóth; László Szekeres; Boglárka Szabó; Bence Bakos; Péter Lakatos
Journal:  Endocrine       Date:  2016-10-07       Impact factor: 3.633

8.  Per oral substitution with 300000 IU vitamin D (Cholecalciferol) reduces bone turnover markers in HIV-infected patients.

Authors:  Rein Jan Piso; Madeleine Rothen; Jean Pierre Rothen; Matthias Stahl; Christoph Fux
Journal:  BMC Infect Dis       Date:  2013-12-06       Impact factor: 3.090

9.  Changes in Dickkopf-1 (DKK1) and Sclerostin following a Loading Dose of Vitamin D 2 (300,000 IU).

Authors:  A Sankaralingam; R Roplekar; C Turner; R N Dalton; G Hampson
Journal:  J Osteoporos       Date:  2014-11-24

Review 10.  Role of Vitamin D in Osteoarthritis: Molecular, Cellular, and Clinical Perspectives.

Authors:  Thomas Mabey; Sittisak Honsawek
Journal:  Int J Endocrinol       Date:  2015-07-02       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.